Rohit Rao, MD
Hematology & Oncology · Jacksonville, FLNPI 1922386085
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $472 of the $532 with a category attached, or 88.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $208 and has fallen 87.8% since, to $25 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 22 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$91
- Pinnacle Biologics, Inc$75
- AstraZeneca$74
- Amgen$43
- Terumo BCT, Inc.$36
- Sanofi$31
- plus $182 from 9 others
Across 12 payments — averaging $30,089 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$188K
- Eli Lilly$173K
What the payments were for
- Food & beverage$47289%
- Education$6011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $91 |
| Pinnacle Biologics, Inc | 1 | $75 |
| AstraZeneca | 2 | $74 |
| Amgen | 3 | $43 |
| Terumo BCT, Inc. | 3 | $36 |
| Sanofi | 2 | $31 |
| Merck | 2 | $29 |
| Genentech, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| AbbVie | 1 | $20 |
| Pfizer | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Exelixis Inc. | 1 | $13 |
How this compares
$532 in reported general payments places this provider in the 20th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 27 | $5,669 |
| Anastrozole | 172 | $3,015 |
| Letrozole | 129 | $2,367 |
| Ondansetron Hcl | 16 | $246 |
| Alendronate Sodium | 14 | $189 |
| Prochlorperazine Maleate | 16 | $176 |
| Dexamethasone | 15 | $120 |
| Lorazepam | 17 | $68 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.